Predictive Factors for Visual Outcome after Treatment for Myopic Choroidal Neovascularization.

Oh, Ha Na; Lee, Joo Eun; Kim, Hyun Woong; Yun, Il Han

doi:2013.54.4.610

J Korean Ophthalmol Soc > Volume 54(4); 2013 > Article

Original Article

Journal of the Korean Ophthalmological Society 2013;54(4):610-617.
DOI: https://doi.org/10.3341/jkos.2013.54.4.610 Published online April 30, 2013.

Predictive Factors for Visual Outcome after Treatment for Myopic Choroidal Neovascularization.

Ha Na Oh, Joo Eun Lee, Hyun Woong Kim, Il Han Yun

¹Department of Ophthalmology, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea. ihyun@inje.ac.kr
²Department of Ophthalmology, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea.

근시성 맥락막 신생혈관의 치료 후 시력 예후와 관련된 예측인자

오하나¹⋅이주은²⋅김현웅¹⋅윤일한¹

Department of Ophthalmology, Busan Paik Hospital, Inje University College of Medicine¹, Busan, Korea
Department of Ophthalmology, Haeundae Paik Hospital, Inje University College of Medicine², Busan, Korea

Abstract

PURPOSE
To determine predictive factors associated with visual outcome after treatment for myopic choroidal neovascularization (mCNV). METHODS: Medical records of the patients who underwent photodynamic therapy (PDT), intravitreal anti-vascular endothelial growth factor (Anti-VEGF) injection, or combination therapy of PDT and Anti-VEGF for myopic CNV, and followed up for more than a year, were reviewed retrospectively. Multiple linear regression analyses were performed to evaluate the predictive factors significantly associated with the visual outcome at 1 year after the treatment. RESULTS: Mean best-corrected visual acuity (BCVA) of 45 eyes of 45 patients showed statistically significant improvement 1 year after the treatment with a mean of 3.5 line improvement (p < 0.01, Wilcoxon signed rank test). Age, 1-month BCVA after treatment and treatment type appeared to be associated with the 1-year visual outcome after treatment for mCNV (p = 0.033, p < 0.001, and p = 0.044, respectively, multivariate linear regression analysis). CONCLUSIONS: Younger age (less than 40 years), better 1-month BCVA after treatment, intravitreal Anti-VEGF monotherapy were associated with improved visual outcome after treatment for mCNV. In particular, 1-month BCVA after treatment is a useful indicator to predict therapeutic response after treatment for mCNV.

Key Words: Anti-VEGF;Bevacizumab;Myopic CNV;PDT;Ranibizumab